Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis

Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis

Abstract Background Immune-related enterocolitis (irEC) is the most common serious complication from checkpoint inhibitors (CPIs). The current front-line treatment for irEC, high-dose corticosteroids (CS), have significant side effects and prolonged therapy may reduce CPI-anti-tumor activity. Early...

Full description

Bibliographic Details
Main Authors: Daniel H Johnson, Chrystia M Zobniw, Van A Trinh, Junsheng Ma, Roland L Bassett, Noha Abdel-Wahab, Jaime Anderson, Jennifer E Davis, Jocelyn Joseph, Marc Uemura, Ali Noman, Hamzah Abu-Sbeih, Cassian Yee, Rodabe Amaria, Sapna Patel, Hussein Tawbi, Isabella C Glitza, Michael A Davies, Michael K Wong, Scott Woodman, Wen-Jen Hwu, Patrick Hwu, Yinghong Wang, Adi Diab
Format: Article
Language:English
Published: BMJ Publishing Group 2018-10-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Infliximab
Immune-related enterocolitis
Immune checkpoint inhibitors
Online Access:http://link.springer.com/article/10.1186/s40425-018-0412-0

Internet

http://link.springer.com/article/10.1186/s40425-018-0412-0

Similar Items